Royalty Pharma (RPRX) Receivables Refunds: 2019-2025
Historic Receivables Refunds for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $28.9 million.
- Royalty Pharma's Receivables Refunds rose 16.06% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 16.06%. This contributed to the annual value of $27.0 million for FY2024, which is 20.31% up from last year.
- According to the latest figures from Q3 2025, Royalty Pharma's Receivables Refunds is $28.9 million, which was up 4.17% from $27.7 million recorded in Q2 2025.
- Over the past 5 years, Royalty Pharma's Receivables Refunds peaked at $28.9 million during Q3 2025, and registered a low of $6.5 million during Q1 2021.
- Its 3-year average for Receivables Refunds is $23.9 million, with a median of $23.6 million in 2024.
- Data for Royalty Pharma's Receivables Refunds shows a peak YoY skyrocketed of 239.82% (in 2021) over the last 5 years.
- Royalty Pharma's Receivables Refunds (Quarterly) stood at $15.0 million in 2021, then surged by 31.58% to $19.8 million in 2022, then increased by 13.35% to $22.4 million in 2023, then grew by 20.31% to $27.0 million in 2024, then climbed by 16.06% to $28.9 million in 2025.
- Its Receivables Refunds stands at $28.9 million for Q3 2025, versus $27.7 million for Q2 2025 and $23.8 million for Q1 2025.